Prognostic Value of Different Metabolic Measurements with Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Resectable Non-Small Cell Lung Cancer: A Two-Center Study  by de Jong, Wouter K. et al.
ORIGINAL ARTICLE
Prognostic Value of Different Metabolic Measurements
with Fluorine-18 Fluorodeoxyglucose Positron Emission
Tomography in Resectable Non-Small Cell Lung Cancer:
A Two-Center Study
Wouter K. de Jong, MD,* Henricus F.M. van der Heijden, MD, PhD,‡ Jan Pruim, MD, PhD,†
Otilia Dalesio, PhD, Wim J.G. Oyen, MD, PhD,¶ and Harry J.M. Groen, MD, PhD*
Introduction: Standard uptake value (SUV) is a quantitative mea-
sure for the preferential uptake of a radiopharmaceutical in a tumor
compared with the homogeneous distribution in the body. SUV can
be based on the maximal value of one pixel (SUVmax) or on the
mean value in a region outlined by isodensity contours. The prog-
nostic value of different SUVs in non-small cell lung cancer
(NSCLC) is not established. We evaluated this value for SUVmax,
SUV70%, and SUV50% among patients with resectable NSCLC.
Methods: All consecutive patients with resectable NSCLC who
underwent an attenuation-corrected whole-body fluorine-18 fluoro-
deoxyglucose positron emission tomography scan from two univer-
sity hospitals were selected. By adjusting the isocontour in the
region of interest on the scan, SUVmax, SUV70%, and SUV50% of
the primary tumor were calculated.
Results: Sixty-six patients (50 male, median age 63 years) were
included. Of the tumors, 16 were pathological stage IA, 23 were IB,
4 were IIA, 14 were IIB, and 9 were IIIA. Median (range) values for
SUVmax, SUV70%, and SUV50% were 6.4 (1.6–19.1), 5.1 (1.0–
15.7), and 4.0 (0.9–13.4), respectively. SUVs were associated with
survival.
Analysis of residuals of SUVmax as a continuous variable in a
Cox’s proportional hazard model for survival suggested no cutoff
point and no indication of time-dependency. Patients with a SUV
higher than the median value had a worse survival than patients with
a SUV lower than median (hazard ratios for SUVmax, SUV70%,
and SUV50% all were 2.9; p  0.02).
Conclusions: SUVmax, SUV70%, and SUV50% measured with
fluorine-18 fluorodeoxyglucose positron emission tomography have
a similar prognostic value, and no “natural” cutoff point for SUV-
max in resectable NSCLC was identified.
Key Words: Non-small cell lung cancer, Fluorine-18 fluorodeoxy-
glucose positron emission tomography, Standard uptake value,
Prognosis.
(J Thorac Oncol. 2007;2: 1007–1012)
Lung cancer is the leading cause of cancer-related death forboth men and women in the Western world, accounting
for more than 160,000 deaths annually in the United States
alone.1 In recent years, fluorine-18 fluorodeoxyglucose
(FDG) positron emission tomography (PET) has acquired a
prominent place in staging non-small cell lung cancer
(NSCLC).2 Staging by PET is superior to conventional stag-
ing with computed tomography (CT). This is largely ex-
plained by the detection of distant metastasis and, to a lesser
extent, by the detection of mediastinal metastases.3 PET scan
results are usually evaluated qualitatively, i.e. visual detec-
tion of increased FDG uptake in the primary tumor alone or
as a visual estimation of the total tumor load,3 estimated with
the tumor-node-metastasis (TNM) staging system.4
Standard uptake values (SUVs) are used to quantita-
tively determine the increased FDG uptake in regions with
increased metabolic activity. SUV is a measure for preferen-
tial FDG uptake in a tumor compared with a homogeneous
distribution in the body. SUVs are defined by drawing re-
gions-of-interest (ROIs) over the tumor. The most commonly
used SUV in the literature is SUVmax, based on the maximal
value in a ROI. In addition, one can easily calculate other
SUVs based on the mean value in a tumor area outlined by
70% and 50% isodensity contours. Our hypothesis was that
such average SUVs better reflect the true metabolic nature of
a tumor compared with SUVmax based on a single pixel
value, and that such average SUVs therefore better predict the
clinical outcome of a patient.
SUVs can be used to compare FDG uptake of tumors of
different individuals or to measure response to chemothera-
py.5 SUVs can also be used to predict survival. Many studies
observed that a higher SUVmax of the primary tumor is
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associated with a worse prognosis,6–15 but the prognostic
value of the metabolic activity seems stronger in early disease
than in advanced disease. Most authors were able to discern
different prognostic groups in early-stage NSCLC based on a
cutoff level that was often arbitrarily chosen. There is not a
good biological reason for a clear cutoff level of SUVs
estimated in tumors.
In the present study, we evaluated the prognostic value
of different SUVs among patients with early-stage NSCLC in
a two-center study. In addition, we explored whether it is
possible to define an appropriate cutoff value for SUVs.
PATIENTS AND METHODS
Patients
All consecutive patients with pathological stage I to
IIIA NSCLC from two university medical centers who un-
derwent an attenuation-corrected whole-body FDG-PET scan
before any treatment were included. Tumor staging was
based on preoperative CT and PET scans, mediastinoscopy if
indicated, and the resected tumor specimen and mediastinal
lymph nodes. Gender, age at diagnosis, performance score,
weight loss, histological subtype, tumor size, completeness of
resection, and treatment with pre- or postoperative chemo-
therapy and/or radiotherapy were recorded. Survival analysis
was censored on June 1, 2006.
To evaluate whether SUV also has prognostic value in
advanced NSCLC, 33 subsequent patients with stage IV
disease from University Medical Center Groningen were
analyzed in an identical method during the same time period.
The present study was performed using anonymized
data that were routinely collected. Therefore, consent was not
specifically obtained and institutional review board approval
was not necessary.
Pet Imaging
All PET scans were performed on Siemens ECAT
scanners (Siemens/CTI, Knoxville, TN) in two clinical PET
Centers (University Medical Centers Groningen and Nijme-
gen) using the same acquisition protocol. The technical spec-
ifications of both Siemens ECAT scanners are similar, and
the devices in both institutions were calibrated according to a
standardized protocol.16 Patients fasted for at least 6 hours
before scanning. Sixty to ninety minutes after intravenous
injection of 220–370 MBq FDG in the forearm, scanning was
started using an interleaved protocol (emission-transmission)
from mid-thigh to the skull. Measurements were performed
consistently for every patient.
All scans were iteratively reconstructed using ordered
subset expectation maximization and were interpreted by
experienced nuclear medicine physicians.
SUV Calculations
ROIs were semi-automatically drawn around the region
of focal FDG uptake in the primary tumor. Semi-automati-
cally means that the tumor is three-dimensionally manually
encircled, so that non-spherical tumors are also entirely
within the ROI. SUV of the primary tumor was calculated by
the following formula: SUV  activity concentration (Mbq/
mL)/(injected dose [MBq]/body weight [g]). SUVmax was
defined as the pixel with the highest FDG uptake within the
ROI. SUV70% and SUV50% were calculated by adjusting
the isodensity contour within the ROI by 70% or 50%,
respectively. SUV70% is the mean SUV of all pixels with an
activity of 70 to 100% of the pixel with the highest FDG
uptake (SUVmax) within the ROI. SUV50% is similarly
calculated by drawing the 50% isodensity contour in the ROI.
SUVs calculated from different scanners cannot gener-
ally be mutually exchanged because of variations in scanning
protocols and software settings. However, the difference
between two scanners is highly consistent and constant, as
was recently demonstrated for our institutions using an-
thropomorphic phantoms and equal settings and recon-
structions.16 The degree of the variation between our two
institutions is approximately 15%.16 To overcome this
inter-institutional variation, a correction factor between
institutions may be calculated. In this study, we performed
the measurements and analyses of SUV using the same
protocol and reconstruction method in both hospitals. In
our patient group, the median stage-specific SUV was not
significantly different between the institutions. Therefore,
we combined the retrospective clinical and raw SUV data
of both institutions into one study.
Statistical Methods
Spearman’s correlation was calculated for the relation
between the different SUVs mutually and between SUV and
tumor size. SUVs of patients with different histology were
compared using the Kruskall-Wallis test. SUVs of patients
with different stages were compared using the Jonckheere test
for ordered alternatives.
Overall survival was defined as the time between PET
scan and date of death or last follow-up. Survival curves were
constructed by means of the Kaplan-Meier technique. Sur-
vival curves for different groups of patients were compared
by means of the log-rank test.
Cox’s proportional hazard regression analysis was used
to evaluate the prognostic value of SUVmax, SUV70%, and
SUV50% and to adjust for other prognostic factors such as
disease stage. p values less than 0.05 were considered statis-
tically significant. The size of the effects was expressed as
hazard ratio (HR) with a 95% confidence interval (CI). A HR
greater than 1 indicates increased mortality. The existence of a
natural SUV cutoff value and time dependency of SUV was
evaluated by means of Martingale and Schoenfeld residuals.17,18
RESULTS
Patient Characteristics
A total of 87 patients were enrolled. Patients who were
not treated by resection (n  11), patients with incomplete
SUV data (n  6), and patients with insulin-dependent
diabetes mellitus (n 4) were excluded. Of the remaining 66
patients (50 male, 16 female) included, median age was 63
years (range, 38-79 years). Performance score was 0 for 20
patients (30%), 1 for 34 (52%), 2 for 4 (6%), and unknown
for 8 patients (12%). Five patients (8%) had more than 10%
weight loss. Seven patients (10%) received preoperative che-
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motherapy consisting of three cycles of a platinum-based
regimen.
Squamous-cell carcinoma was found in 35 patients
(53%), adenocarcinoma in 23 patients (35%), large-cell car-
cinoma in 7 patients (11%), and bronchoalveolar cell carci-
noma in 1 patient (1%). Sixteen patients (24%) had patho-
logical disease stage IA, 23 patients (35%) had stage IB, 4
patients (6%) had stage IIA, 14 patients (21%) had stage IIB,
and 9 patients (14%) had stage IIIA. Median tumor size was
3.1 cm (range, 0.9–12 cm). At the time of analysis, 25
patients were deceased. The median overall survival of these
patients was 1.7 years (range, 0.1–5.7 years). The median
follow-up time for living patients was 3.2 years (range,
0.9–5.9 years).
Relation of SUV and Patient Characteristics
Median SUVmax was 6.4 (range, 1.6-19.1), median
SUV70% was 5.1 (range, 1.0-15.7), and median SUV50%
was 4.0 (range, 0.9-13.4). The distribution of SUVmax,
SUV70%, and SUV50% were skewed to the right. SUVmax,
SUV70%, and SUV50% were highly correlated with each
other; Spearman’s correlation coefficients for SUVmax and
SUV70% and SUV50%, and for SUV70% and SUV50%
were 0.993, 0.990, and 0.997, respectively.
Median SUVs did not differ significantly among histolog-
ical types of NSCLC: median SUVmax was 7.1 (range, 2–19)
for patients with squamous carcinoma, 6.3 (range, 2–15) for
patients with adenocarcinoma, and 5.6 (range, 3–19) for large
cell carcinoma.
SUVmax, SUV70%, and SUV50% all increased with
increasing disease stage (Jonckheere tests all p  0.001).
Median SUVmax for patients with pathological stage IA, IB,
IIA, IIB, and IIIA was 3.7, 5.6, 5.0, 8.2, and 9.9, respectively
(Figure 1). A larger tumor size was correlated with a higher
SUVmax (Spearman’s correlation coefficient 0.565).
Exploring a Cutoff Point for SUV
SUVmax, SUV70%, and SUV50% as continuous vari-
ables were all significantly associated with survival (p 
0.018, p  0.012, and p  0.011, respectively). For the
self-chosen cutoff points 7, 8, 9, and 10, SUVmax signifi-
cantly predicted survival, as shown in Figure 2.
Analysis of Martingale and Schoenfeld residuals of
SUVmax as a continuous variable suggests that an increasing
value of SUVmax is associated with an increased risk of
death without showing a real cutoff value (Figure 3). Because
of this, the median values are chosen to dichotomize the data
and present survival curves. This has the advantage of divid-
ing the patients into groups of similar size.
SUV and Prognosis
SUVmax, SUV70%, and SUV50% dichotomized at
their median value predicted survival (HR 2.93 [95% CI
1.21–7.09] for all three SUVs). Patients with SUVmax higher
than median value had a worse overall survival compared
with patients with a lower SUVmax (Figure 4). All 66
patients had a tumor resection, and 58 (88%) achieved a
complete resection. SUVmax dichotomized at the median
value predicted disease-free survival after complete resection
(p  0.03). Seven patients with an incomplete resection
received postoperative thoracic radiotherapy.
Pathological disease stage (p  0.001) and tumor size
(p  0.007) univariately predicted survival, whereas gender,
performance score, age older or younger than 65 years,
weight loss, preoperative chemotherapy, and histological sub-
type did not predict survival.
Adjustment by stage in a multivariable analysis showed
that SUVmax (and SUV70 or SUV50) provided additional
prognostic information beyond pathological disease stage
(p  0.051, p  0.041, p  0.041, respectively).
Prognostic Value of SUV in Advanced NSCLC
In contrast to the patients with early, resectable disease,
no difference in overall survival was observed (p  0.949)
for the 33 patients with stage IV NSCLC after dichotomizing
at their median SUVmax (9.4).
DISCUSSION
To our knowledge, this is the first clinical study to
compare different SUVs in NSCLC. One pixel with maximal
value within the whole primary tumor, 30% of the pixels with
the highest metabolic activity, or even half of the pixels with
the highest activity have similar prognostic impact in resect-
able NSCLC. Nevertheless, pathological TNM disease stage
FIGURE 1. Distribution of median SUVmax according to
pathological tumor stage (p  0.001).
FIGURE 2. Relationship among various cutoff levels of SUV-
max and their discriminative value for overall survival esti-
mated by univariate analysis. A p value 0.05 is considered
significant.
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estimated with CT or PET remains the strongest independent
prognostic factor. Another finding was that no “natural”
cutoff point for SUVmax was observed in resectable NSCLC.
In addition, the present study is the first two-center study
evaluating the prognostic effect of SUV in NSCLC.
Methodological studies show that, provided they are
measured with the same equipment and reconstruction meth-
ods, SUVmax and average SUV within a ROI are closely
correlated,19–21 as they were in the present study. Therefore,
it does not seem surprising that they are equally able to
predict prognosis. One could, however, argue that an average
SUV better represents the true metabolic nature of a tumor
and subsequently better reflects the clinical outcome of a
patient than the metabolic information coming from a single
pixel. However, our data suggest that SUVmax measured in
the primary tumor is as effective as SUV70% and SUV50%,
and SUVmax is the easiest SUV to calculate.
The accuracy of SUV can be influenced by several
factors, of which ROI defining, image reconstruction, tracer
administration, scanning time, and patient factors such as
glucose metabolism and body weight are most well
known.20,22,23 We diminished this variability of SUV by using
the same scanning and reconstruction protocol in both insti-
tutions, because a previously performed study and results
from this study showed that the differences between our insti-
tutions were highly consistent and constant.16 In addition, the
interobserver and intraobserver agreement in SUVs was found
to be excellent.24 These findings show that SUVmax is an easily
reproducible and reliable prognostic parameter, permitted that
the same scanning and reconstruction settings are used or a
correction factor is applied between different institutions.
In contrast with several other reports,6,8,10–13 none of
the SUVs could be identified as an independent prognostic
factor in multivariate analysis. In their series of 100 patients
with resected NSCLC, Downey et al. found that SUVmax
greater than 9 (their observed median value) and primary
tumor size larger than 3 cm and their interaction significantly
predicted survival.12 In our study, the SUVmax was associ-
ated with survival even when adjusting for stage of disease.
In a large study with 315 patients planned for resection,
SUVmax higher or lower than the median value was the
strongest prognostic factor, stronger than disease stage I/II
versus III /IV and even complete resection.13 Similarly, in
Sasaki et al.’s study of patients with early-stage NSCLC,
SUVmax dichotomized at 5 and tumor size were independent
predictors for survival, whereas nodal status and treatment
were not.6 Noteworthy, most of these studies use tumor size
(T) without NM status. TNM disease stage is more powerful
in predicting survival of resectable tumors than T status
alone.4 Therefore, the difference between these previous
studies and our findings could be explained by the fact that
we tested all separate TNM disease stages (IA to IIIA) instead
of only T status in multivariate analysis. Interestingly, Ve-
selle et al. recently reported that the correlation of SUVmax
with tumor stage disappeared after correcting tumors smaller
than 3 cm for partial volume effects.25 It is indisputable that
SUVmax has prognostic value, although the strength of its
effect varies among the reported studies.26
FIGURE 3. Martingale residuals for
a null model, suggesting that an in-
creasing value of SUVmax is associ-
ated with an increased risk of death
without showing a real cutoff value.
FIGURE 4. Overall survival for 66 patients according to
SUVmax, dichotomized at median value (6.4).
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It is not clear which factor is most important in the
prognosis of NSCLC. Two suitable candidates are the total
tumor load in the body as expressed by TNM status and the
biological behavior of the primary tumor as expressed by
SUV, or perhaps a combination of these two factors. For
example, if tumor load is high, as in advanced NSCLC, SUV
may not have additional prognostic power, in contrast to
cases with a low tumor load, such as early-stage NSCLC, in
which metabolic activity of a tumor may play an important
role. Based on these assumptions, one would expect that
SUVmax would not be associated with survival in stage IV
NSCLC. This is supported by our finding that SUVmax did
not predict survival in 33 consecutive patients with stage IV
NSCLC, in line with the observations of Lee et al. in ad-
vanced disease.27 In addition, although median SUV gener-
ally increases with increasing disease stage, this increase is
more pronounced for the lower disease stages, in contrast
with the hardly noteworthy increase between the higher
disease stages, such as IIIB and IV.13 This is in agreement
with the loss of prognostic value of SUV in the more
advanced disease stages. Therefore, SUV seems to be most
useful in early-stage NSCLC.
Some groups have proposed data-driven cutoff values
of SUV by calculating post hoc the discriminative value
(expressed as p value) for several self-chosen cutoff points.
The cutoff point with the lowest p value was then considered
the most suitable, regardless of the number of patients in the
groups above and below the cutoff value.6,8–11 By applying
the same method, we observed that SUV is a predictor for
survival for several different cutoff values, but we question
whether this methodology is appropriate. First, this method-
ology may lead to overestimation because it is data-driven
and because of the effects of multiple testing.28 Second, there
is no biological reason for a cutoff level phenomenon in
tumors. SUV represents FDG uptake in a tumor caused by the
up-regulation of trans-membrane glucose receptors GLUT 1
and GLUT 329 and consequently is an indirect measurement
for proliferation. The extent of this up-regulation represents
as a continuous variable. In addition, SUVmax is highly
correlated with Ki-67 expression, a marker of cell prolifera-
tion.30 It is therefore plausible that no natural cutoff point for
SUV was observed.
In conclusion, our two-center study showed that SUV-
max, SUV70%, and SUV50% have similar prognostic impact
in resectable NSCLC. In the absence of a biological cutoff
point, the median SUVmax of the primary tumor, which
divides the patients into groups of similar size, may be used.
An interesting application of such a strong prognostic indi-
cator as SUV is its use as a stratification parameter in trials
involving adjuvant chemotherapy.
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